Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Charley’s Fund
NEW YORK, Oct. 2, 2013 /PRNewswire/ -- Charley's Fund, an organization dedicated to finding a treatment and cure for Duchenne Muscular Dystrophy (Duchenne), announced its fourth annual Race Against Time fundraiser run will take place on Sunday, October 6 in Central Park. The race will be attended by more than 250 runners of all ages from across the country, with the goal of raising money to support research in Duchenne, the most common fatal genetic disorder to affect children around the world.
Duchenne is characterized by progressive muscle degeneration and weakness, which typically begins in patients between the ages of three and five. This disease has a 100 percent fatality rate, with most children succumbing to it in their late teens or early 20s. Sufferers born with the disease, primarily boys, are unable to produce dystrophin, a protein essential for muscle strength and function. Finding a cure for Duchenne is truly a Race Against Time.
Charley Seckler, for whom Charley's Fund is named, was diagnosed with Duchenne in 2004. After hearing Charley's diagnosis, his parents, Tracy and Benjamin, immediately set their sights on supporting the search for a cure. Through Charley's Fund, they have contributed more than $25 million dollars to the effort to treat and cure Duchenne. The fundraising goal for this year's Race Against Time is $200,000.
This year's supporters include a team of 60+ cadets from West Point and Martin Bashir, a political commentator for MSNBC and correspondent for Dateline NBC.
To register, please visit http://www.firstgiving.com/CharleysFund/4th-annual-race-against-time.
To donate, please visit https://www.charleysfund.org/donate/.
Contact: Ellen Wilner, 646-388-3257, Ellen@charleysfund.org
©2012 PR Newswire. All Rights Reserved.